Comparing Hemophilia A Therapies: Efficacy and Safety Insights

EP: 1.Management Insights for Patients With Hemophilia

EP: 2.Coverage Decisions for Expensive Hemophilia Treatments

EP: 3.Impact of ICER Reports on Hemophilia Treatment Decisions

EP: 4.Enhancing Provider Access and Expertise for Rare Disease Care

EP: 5.Factors Impacting Hemophilia A Care Costs

EP: 6.Collaborative Strategies in Hemophilia A Care Cost Management

EP: 7.Strategies to Manage Medication Costs and Waste

EP: 8.Adapting to Novel Hemophilia A Treatments

EP: 9.Comprehensive Insights into Hemophilia A: Prevalence, Clinical Impact, and Economic Considerations

EP: 10.Evolution of the Hemophilia A Treatment Landscape: Innovations and Guidelines

EP: 11.Hemophilia A Treatment Factors and Outcomes

EP: 12.Prophylactic Treatment Challenges and Considerations for Hemophilia A

EP: 13.Consequences of Nonadherence in Hemophilia A

EP: 14.Advancements in Hemophilia A Therapies

Now Viewing

EP: 15.Comparing Hemophilia A Therapies: Efficacy and Safety Insights

EP: 16.Real-World Insights: Factor vs Emicizumab in Hemophilia A

EP: 17.Emicizumab Dosing: Prophylaxis and Bleeding Management

EP: 18.Optimizing Hemophilia Treatment: Strategies and Adherence

EP: 19.Advancements in Hemophilia A Therapies: Altuviiio and Roctavian

EP: 20.Advancements in Hemophilia A Treatment: Fitusiran and the Evolving Landscape

This is a video synopsis/summary of an Insights featuring Steven W. Pipe, MD.

Pipe compares the safety profiles of factor prophylaxis and emicizumab in treating hemophilia A. While emicizumab prophylaxis generally proves superior in efficacy, Pipe discusses nuances in specific patient groups. He delves into the risks associated with factor replacement therapy, emphasizing factor inhibitors and the challenges of maintaining adequate trough levels. The introduction of extended half-life agents, such as Altuviiio, shows promise in addressing some limitations. Emicizumab, a bispecific antibody, offers subcutaneous delivery and steady-state hemostasis but has limitations, including breakthrough bleeds and the absence of individualized dosing. Pipe highlights concerns about the lack of natural physiologic regulation with emicizumab, raising questions about potential thrombotic complications. He reflects on observed issues during clinical trials, such as thrombotic events in the inhibitor population, attributing them to specific concomitant treatments. The discussion extends to long-term safety considerations, contrasting the morbidity associated with factor VIII inhibitors and chronic arthropathy in factor replacement therapy with the potential nonhemostatic roles of factor VIII in bone health. While emicizumab minimizes factor VIII inhibitor impact, the interview emphasizes the need for ongoing studies, including registry data and observational research, to comprehensively evaluate the long-term safety of these evolving hemophilia A therapies.

Video synopsis is AI-generated and reviewed by AJMC^® editorial staff.